Mirati Therapeutics Inc. (MRTX)

Oncology Corporate Profile

Stock Performance

5.1500
-0.0500

HQ Location

9363 Towne Centre Drive, Suite 200
San Diego, CA 92121

Company Description

Mirati Therapeutics is a publicly-traded biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer. Our compounds result from internal chemistry efforts targeting the active sites of enzymes that are key drivers of tumor growth. Our clinical development programs are focused on treating selected tumor types that express high levels of these targets in order to most effectively address unmet patient needs. Our lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. We are also evaluating development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor and MGCD516, a kinase inhibitor with a distinct target profile.

Website: http://www.mirati.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
mocetinostatHDAC inhibitorBladder cancerII
mocetinostatHDAC inhibitorDiffuse large B-cell Lymphoma (DLBCL)II
mocetinostatHDAC inhibitorMyelodysplastic Syndrome (MDS)II
MGCD265multiple tyrosine kinase inhibitorHead & Neck cancerI
MGCD265multiple tyrosine kinase inhibitorNon Small Cell Lung Cancer (NSCLC)I
mocetinostat (+ MEDI4736)HDAC inhibitorVarious cancer typesIMedimmune
MGCD516multiple tyrosine kinase inhibitorVarious cancer typesI

View additional information on product candidates here »

Source


http://www.mirati.com

Recent News Headlines

Mirati reports 4Q loss

3/9/2017 11:04 pm

Mirati reports 4Q loss

3/9/2017 11:04 pm

Mirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016

3/9/2017 09:00 pm

[PR Newswire] - SAN DIEGO, March 9, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) ("the Company," "we," "our," "us," or "Mirati") today reported financial ...

Mirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference

2/13/2017 09:00 pm

[PR Newswire] - SAN DIEGO, Feb. 13, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D, Ph.D., President and CEO of Mirati, will provide a corporate overview during ...

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

1/6/2017 12:05 pm

[at noodls] - January 6, 2017 SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 4,350,176 shares of its common stock at ...

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

1/6/2017 12:03 pm

[PR Newswire] - SAN DIEGO, Jan. 6, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the pricing of an underwritten public offering of 4,350,176 shares of its common stock at a price to the public of $5.60 per share. In addition, and in lieu of common stock, Mirati is offering to funds affiliated with Boxer Capital, LLC pre-funded warrants to purchase up to an aggregate of 7,258,263 shares of common stock at a purchase price of $5.599 per warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds from this offering are expected to be approximately $65.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. Mirati has granted the underwriters a 30-day option to purchase up to an additional 652,526 shares of common stock in connection with the public offering.

Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs

1/5/2017 09:05 pm

[at noodls] - January 5, 2017 Glesatinib demonstrates improved tolerability with new spray dried dispersion formulation; Promising clinical activity observed in NSCLC patients with MET mutations; Early clinical responses ...

Mirati Therapeutics Announces Proposed Public Offering of Common Stock

1/5/2017 09:05 pm

[at noodls] - January 5, 2017 SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its ...

Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs

1/5/2017 09:00 pm

[PR Newswire] - SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (Mirati or the Company) (MRTX) today announced data from two ongoing clinical programs, including the Phase 1b and Phase 2 trials of glesatinib, a spectrum selective kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET, and the Phase 1b trial of sitravatinib, a receptor tyrosine kinase inhibitor for the treatment of genetically-selected NSCLC and other solid tumors. "The transition to the new spray dried dispersion (SDD) formulation of glesatinib has succeeded in improving tolerability, resulting in significantly fewer formulation-specific side effects in patients with NSCLC.

Mirati Therapeutics Announces Proposed Public Offering of Common Stock

1/5/2017 09:00 pm

[PR Newswire] - SAN DIEGO, Jan. 5, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares are being offered by Mirati.

Mirati reports 3Q loss

11/3/2016 11:00 pm